These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38295624)

  • 1. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.
    Hardwick RN; Fisher CD; Canet MJ; Scheffer GL; Cherrington NJ
    Drug Metab Dispos; 2011 Dec; 39(12):2395-402. PubMed ID: 21878559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Transporters Alternations Associated with Non-alcoholic Fatty Liver Disease (NAFLD): A Systematic Review.
    Omidkhoda N; Zare S; Mahdiani S; Samadi S; Akhlaghi F; Mohammadpour AH
    Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):1-10. PubMed ID: 36319903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Hardwick RN; Cherrington NJ
    Liver Int; 2017 Jul; 37(7):1074-1081. PubMed ID: 28097795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.
    Cobbina E; Akhlaghi F
    Drug Metab Rev; 2017 May; 49(2):197-211. PubMed ID: 28303724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.
    Canet MJ; Merrell MD; Hardwick RN; Bataille AM; Campion SN; Ferreira DW; Xanthakos SA; Manautou JE; A-Kader HH; Erickson RP; Cherrington NJ
    Drug Metab Dispos; 2015 Jun; 43(6):829-35. PubMed ID: 25788542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
    Marie S; Frost KL; Hau RK; Martinez-Guerrero L; Izu JM; Myers CM; Wright SH; Cherrington NJ
    Acta Pharm Sin B; 2023 Jan; 13(1):1-28. PubMed ID: 36815037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition.
    Marin JJG; Cives-Losada C; Macias RIR; Romero MR; Marijuan RP; Hortelano-Hernandez N; Delgado-Calvo K; Villar C; Gonzalez-Santiago JM; Monte MJ; Asensio M
    Biochem Pharmacol; 2024 Mar; ():116166. PubMed ID: 38527556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does hepatic steatosis affect drug metabolizing enzymes in the liver?
    Buechler C; Weiss TS
    Curr Drug Metab; 2011 Jan; 12(1):24-34. PubMed ID: 21222589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
    Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox.
    Özvegy-Laczka C; Ungvári O; Bakos É
    Biochem Pharmacol; 2023 Mar; 209():115448. PubMed ID: 36758706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
    Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
    Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.
    Hardwick RN; Clarke JD; Lake AD; Canet MJ; Anumol T; Street SM; Merrell MD; Goedken MJ; Snyder SA; Cherrington NJ
    Toxicol Sci; 2014 Nov; 142(1):45-55. PubMed ID: 25080921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury.
    Malinen MM; Ali I; Bezençon J; Beaudoin JJ; Brouwer KLR
    Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G597-G609. PubMed ID: 29420067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug transport proteins in the liver.
    Faber KN; Müller M; Jansen PL
    Adv Drug Deliv Rev; 2003 Jan; 55(1):107-24. PubMed ID: 12535576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.
    Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C
    Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination.
    Frost KL; Jilek JL; Sinari S; Klein RR; Billheimer D; Wright SH; Cherrington NJ
    Drug Metab Dispos; 2023 Feb; 51(2):155-164. PubMed ID: 36328481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD.
    Murphy WA; Diehl AM; Loop MS; Fu D; Guy CD; Abdelmalek MF; Karachaliou GS; Sjöstedt N; Neuhoff S; Honkakoski P; Brouwer KLR
    Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38381537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.